U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H48N2O8S
Molecular Weight 572.754
Optical Activity UNSPECIFIED
Defined Stereocenters 11 / 11
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAUROGLYCOCHOLIC ACID

SMILES

[H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)NCC(=O)NCCS(O)(=O)=O

InChI

InChIKey=URJQSMIFSMHWSP-VVHBOOHCSA-N
InChI=1S/C28H48N2O8S/c1-16(4-7-24(34)30-15-25(35)29-10-11-39(36,37)38)19-5-6-20-26-21(14-23(33)28(19,20)3)27(2)9-8-18(31)12-17(27)13-22(26)32/h16-23,26,31-33H,4-15H2,1-3H3,(H,29,35)(H,30,34)(H,36,37,38)/t16-,17+,18-,19-,20+,21+,22-,23+,26+,27+,28-/m1/s1

HIDE SMILES / InChI
Sodium tauroglycocholate presents in ENZAR FORTE tablet, together with enzymes: amylase, lipase and protease. ENZAR FORTE is indicated for the treatment of the following digestive symptoms: indigestion/dyspepsia; flatulence; bloating; fullness after eating; heartburn; anorexia; hepatic and pancreatic insufficiency; post-operative digestive upsets and convalescence. Discomfort, flatulence, and abdominal colic may result when the bodies own pancreatic enzymes cannot cope with excessive quantities of food consumed. In such cases, the enzymes present in ENZAR FORTE enhance the digestive processes in a natural way, thereby reducing the amount of undigested food available for fermentation & putrefaction. Amylase enzyme helps in the digestion of starch, lipase is involved in the digestion of lipids, and protease is required for digestion of proteins. The advantage of bile salt i.e. sodium tauroglycocholate for improving absorption of fat & fat-soluble vitamins.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Biliary acid transporting system
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
Palliative
ENZAR FORTE

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Some cardiovascular actions of sodium tauroglycocholate.
1974 Apr-Jun
Biliary excretion and pharmacokinetics of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging in the rat.
1993 Aug
Effects of various penetration enhancers on penetration of aminophylline through shed snake skin.
2014 Feb
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Each enteric-coated tablet contains: Amylase activity -15,000 USP units; Lipase activity - 4,000 USP units; Protease activity - 15,000 USP units of (derived from Pancreatin USP) Sodium tauroglycocholate BPC – 65mg (with sugar coating containing essential carminative oils).
As a digestive enzyme: 1 tablet to be sucked (not chewed) for few seconds and then swallowed with every meal. In pancreatic insufficiency: Up to 2 tablets 2-3 times a day can also be given. But dosage is individualized depending on patient’s pancreatic function.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
TAUROGLYCOCHOLIC ACID
Common Name English
ETHANESULFONIC ACID, 2-(((((3.ALPHA.,5.BETA.,7.ALPHA.,12.ALPHA.)-3,7,12-TRIHYDROXY-24-OXOCHOLAN-24-YL)AMINO)ACETYL)AMINO)-
Systematic Name English
GLYCOTAUROCHOLIC ACID
Common Name English
Code System Code Type Description
CAS
26198-66-3
Created by admin on Sat Dec 16 14:16:13 GMT 2023 , Edited by admin on Sat Dec 16 14:16:13 GMT 2023
PRIMARY
FDA UNII
VV181JY3L5
Created by admin on Sat Dec 16 14:16:13 GMT 2023 , Edited by admin on Sat Dec 16 14:16:13 GMT 2023
PRIMARY
PUBCHEM
119420
Created by admin on Sat Dec 16 14:16:13 GMT 2023 , Edited by admin on Sat Dec 16 14:16:13 GMT 2023
PRIMARY